anti-mIR-155 therapy (Regulus/Washington University in St Louis)

N/A

Report date: 2025/03/14 18:14:22
NME

Base Information

Drug Nameanti-mIR-155 therapy (Regulus/Washington University in St Louis)
Drug Alias Nameanti-mIR-155 therapy (Regulus/GlaxoSmithkline)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisenseSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > microRNA
Mechanisms of ActionImmunomodulators
TargetsUpdating
Therapy Area/IndicationsInflammationImmune System DiseasesAmyotrophic Lateral Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCalifornia Institute Of Technology
China Registration ClassN/A

Develop Information

Active CompaniesRegulus Therapeutics IncWashington University
Inactive CompaniesIonis Pharmaceuticals IncGlaxosmithkline PlcAlnylam Pharmaceuticals Inc +[4] 
Active IndicationsAmyotrophic Lateral Sclerosis
Inactive IndicationsInflammationImmune System Diseases

Other Information

ATC CodeN/A
Related LinksN/A